Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05405361 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
A Phase 2 study of Multifocal Motor Neuropathy (MMN), sponsored by argenx.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 20
- Study locations
NCT05405361: Active Phase 2 study of Multifocal Motor Neuropathy (MMN), sponsored by argenx.
NCT05405361 is a Phase 2 study of Multifocal Motor Neuropathy (MMN) that is active but no longer recruiting, run by argenx. The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05405361, a Phase 2 study of Multifocal Motor Neuropathy (MMN), is active but no longer recruiting, sponsored by argenx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety and tolerability, efficacy, immunogenicity, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ARGX-117 Intravenously (IV) in adults with Multifocal Motor Neuropathy (MMN). The trial will include a double-blinded rollover treatment period (DTP), an open-label treatment period (OTP), and a safety follow-up period.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL ARGX-117
Study Locations (20)
Other
- Medizinische Universitat Wien (Medical University of Vienna) - Vienna
- AZ Sint-Lucas - Ghent
- University Health Network - Toronto
- CHU Bordeaux - Groupe Hospitalier Pellegrin - Bordeaux
- Hôpital Roger Salengro (CHU de Lille) - Lille
- CHU de Nice - Nice
- Hôpital de la Pitié Salpétrière - Paris
- Universitätsklinikum Essen - Essen
- Universitatsmedizin Gottingen (UMG) Georg-August-Universitaet - Göttingen
- IRCCS Ospedale San Raffaele S.r.l. - Milan
- Azienda Ospedaliero Universitaria Pisana - Pisa
- Azienda Ospedaliera Sant' Andrea - Rome
- IRCCS Humanitas Research Hospital - Rozzano
- Universitair Medisch Centrum Utrecht - Utrecht
Arizona
- HonorHealth Neurology - Scottsdale
Illinois
- NorthShore University HealthSystem - Glenview
Minnesota
- University of Minnesota - Minneapolis
Ohio
- The Cleveland Clinic Foundation - Cleveland
Pennsylvania
- University of Pennsylvania - Perelman Center for Advanced Medicine - Philadelphia
Texas
- Austin Neuromuscular Center - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-01-18 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 2 |
What the registry record for NCT05405361 still lists
NCT05405361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Multifocal Motor Neuropathy (MMN) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05405361 names 20 study sites across 7 states, led by Other, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT05405361 about?
NCT05405361 is a clinical study titled "A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy". This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety and tolerability, efficacy, immunogenicity, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ARGX-117 Intravenously (IV) in adults with Multifocal Mo...
What is the current status of trial NCT05405361?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2023-01-18. Estimated completion is 2029-09-30.
What conditions does trial NCT05405361 study?
This clinical trial studies the following conditions: Multifocal Motor Neuropathy (MMN).
What interventions are being tested in trial NCT05405361?
The interventions under investigation include: Placebo (OTHER), ARGX-117 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05405361?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05405361 being conducted?
This trial has 20 study locations across Arizona, Illinois, Minnesota, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multifocal Motor Neuropathy (MMN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05405361's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI